Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?

European Journal of Cancer(2022)10.1016/j.ejca.2022.12.011Source: DataRank Database

The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet? is a research paper published in European Journal of Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 4.04)OA: hybridTopics (27)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

William M Drake ORCID,Samra Turajlic ORCID,Scott T.C. Shepherd ORCID

Live enrichment

PubMed:36708612 OpenAlex:https://openalex.org/W4312054325

Barts Charity

Grant: MGU0319

Cancer Research UK

Grant: C50947/A18176

Rosetrees Trust

Grant: A2204

Cancer Research UK

Grant: 18176

Melanoma Research Alliance

Grant: 686061

National Institutes of Health Clinical Center

Grant: U01 CA247439

National Institute for Health Research (NIHR)

Grant: ACF-2016-22-002

Cancer Research UK

Grant: 29911

Cancer Research UK

Grant: CC2044

Institute of Cancer Research

Grant: A109

Barts Charity

Grant: MRD0191

Manchester Biomedical Research Centre

National Institutes of Health

Wellcome Trust

Royal Marsden Cancer Charity

Medical Research Council

The National Institute for Health Research Biomedical Research Centre for cancer

FWCI

4.04

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ejca.2022.12.011

publisherhttps://doi.org/10.1016/j.ejca.2022.12.011

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36708612

repositoryhttps://figshare.com/articles/journal_contribution/The_road_to_systemic_therapy_in_von_Hippel-Lindau_VHL_disease_Are_we_there_yet_/21975845

repositoryhttps://doi.org/10.25418/crick.21975845.v1

Fields of Study

Cancer, Hypoxia, and MetabolismCancer-related Molecular PathwaysAdrenal and Paraganglionic Tumors

MeSH Terms

Carcinoma, Renal Cellvon Hippel-Lindau DiseaseHumansIndenesKidney NeoplasmsQuality of LifeNeuroectodermal Tumors, PrimitiveBasic Helix-Loop-Helix Transcription FactorsBasic Helix-Loop-Helix ProteinsVon Hippel-Lindau Tumor Suppressor Protein

Keywords

MedicineVon Hippel–Lindau diseaseDiseasePenetranceSystemic therapyOncologyInternal medicineCancerBioinformaticsGeneBiologyHereditary Cancer SyndromeVhl DiseaseBelzutifan

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 2 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721087.v1figshare

Additional file 2 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721087figshare

Additional file 8 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721105.v1figshare

Additional file 8 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721105figshare

Additional file 12 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721117.v1figshare

Additional file 12 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721117figshare

Additional file 10 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721111.v1figshare

Additional file 16 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721129.v1figshare

Additional file 13 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721120.v1figshare

Additional file 15 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721126figshare

Additional file 13 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721120figshare

Additional file 4 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721093.v1figshare

Additional file 4 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721093figshare

Additional file 17 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721132.v1figshare

Additional file 6 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721099.v1figshare

Additional file 17 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721132figshare

Additional file 5 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721096.v1figshare

Additional file 16 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721129figshare

Additional file 14 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721123.v1figshare

Additional file 5 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721096figshare